Scientists hunt for clues to predict immunotherapy success in head and neck cancer
NCT ID NCT04603248
First seen Feb 13, 2026 · Last updated May 13, 2026 · Updated 13 times
Summary
This study aims to find immune system markers that can predict how well the drug nivolumab works in people with recurrent or metastatic head and neck squamous cell carcinoma. Researchers will analyze tumor tissue and blood samples from 50 participants to look for these markers. The goal is to better identify which patients are most likely to benefit from this treatment.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEAD AND NECK SQUAMOUS CELL CARCINOMA HNSCC are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Yonsei Severance Hospital
Seoul, South Korea
Conditions
Explore the condition pages connected to this study.